COVID-19 Disease Burden in the Omicron Variant-Dominated Endemic Phase: Insights from the ROUTINE-COV19 Study Using Real-World German Statutory Health Insurance Data
Viruses · 2025
DOI: 10.3390/v17030424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Sabrina Müller und 7 weiteren Autor:innen. Beteiligte Einrichtung: GIPAM GmbH, 23966 Wismar, Germany. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Cost of Illness. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioNTech (Germany), BioNTech Europe GmbH.
Abstract (Originalsprache)
The ROUTINE-COV19 study explores the burden of COVID-19 in Germany during the early endemic phase, assessing disease patterns and their impact on the healthcare system from 1 July 2022 to 30 June 2023. Using anonymized statutory health insurance data from over 3 million individuals in Thuringia and Saxony, COVID-19 cases were identified through diagnostic codes, with severe and critical cases defined by hospitalization and intensive care criteria. The study focused on high-risk populations as identified by the German Immunization Technical Advisory Group. During the study period, 414,648 new COVID-19 cases were documented, with peaks in October 2022 and March 2023. Severe cases occurred at a rate of 241.6 per 100,000 persons, with in-hospital mortality exceeding 12%. Critical cases requiring intensive care had an in-hospital mortality rate of 32.2%. COVID-19-related hospitalizations averaged 9.94 days, generating direct costs of EUR 64.9 million, while indirect costs from work absenteeism amounted to EUR 454.3 million, representing 7.5% of all-cause absenteeism costs. Despite entering an endemic phase, COVID-19 continues to pose a substantial burden, particularly among older adults and those with pre-existing cardiovascular conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GIPAM GmbH, 23966 Wismar, Germany.
- BioNTech Europe GmbH, 10179 Berlin, Germany.
- Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), 23966 Wismar, Germany.
- Pfizer Inc., New York, NY 10017, USA.
- AOK PLUS, 07743 Jena, Germany.
- Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
ORCID-Profile: Sabrina Müller, Andrea Schmetz, Jingyan Yang, Christoph D Spinner
Förderung
- BioNTech (Germany)
- BioNTech Europe GmbH
Zitieren
APA
Müller, S., Schmetz, A., Knaul, J. K., Wilke, T., Yang, J., Dornig, S., Lehmann, C., & Spinner, C. D. (2025). COVID-19 Disease Burden in the Omicron Variant-Dominated Endemic Phase: Insights from the ROUTINE-COV19 Study Using Real-World German Statutory Health Insurance Data. Viruses. https://doi.org/10.3390/v17030424
Vancouver
Müller S, Schmetz A, Knaul JK, Wilke T, Yang J, Dornig S, et al. COVID-19 Disease Burden in the Omicron Variant-Dominated Endemic Phase: Insights from the ROUTINE-COV19 Study Using Real-World German Statutory Health Insurance Data. Viruses. 2025. doi:10.3390/v17030424
BibTeX
@article{Mller2025,
author = {Müller, Sabrina and Schmetz, Andrea and Knaul, Julia K and Wilke, Thomas and Yang, Jingyan and Dornig, Sabine and Lehmann, Clara and Spinner, Christoph D},
title = {COVID-19 Disease Burden in the Omicron Variant-Dominated Endemic Phase: Insights from the ROUTINE-COV19 Study Using Real-World German Statutory Health Insurance Data},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17030424}
}
EUVIMED